



## Lineage to Present at the 2022 Virtual Growth Conference Presented by Maxim Group LLC on March 28, 2022

March 24, 2022

CARLSBAD, Calif.--(BUSINESS WIRE)--Mar. 24, 2022-- [Lineage Cell Therapeutics, Inc.](#) (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced that Brian M. Culley, the Company's Chief Executive Officer, will be presenting at the [2022 Virtual Growth Conference](#), presented by Maxim Group LLC and hosted by M-Vest. Mr. Culley will be participating in an "Ophthalmology Panel" hosted by Jason McCarthy, Ph.D., Senior Managing Director, Biotechnology, on March 28<sup>th</sup>, 2022 at 10am ET / 7am PT. Mr. Culley will also provide a corporate overview which will be available to investors on demand, starting on Monday March 28<sup>th</sup>, 2022.

The live panel and on-demand presentation will be available to registered users directly through the M-Vest platform: <https://m-vest.com/events/2022-virtual-growth-conference>. Registration is required for conference participation. An archived webcast of the corporate presentation will also be available on the [Events and Presentations](#) page of the Lineage website. Additional videos are available on the [Media](#) page of the Lineage website.

### About Lineage Cell Therapeutics, Inc.

Lineage Cell Therapeutics is a clinical-stage biotechnology company developing novel cell therapies for unmet medical needs. Lineage's programs are based on its robust proprietary cell-based therapy platform and associated in-house development and manufacturing capabilities. With this platform Lineage develops and manufactures specialized, terminally differentiated human cells from its pluripotent and progenitor cell starting materials. These differentiated cells are developed to either replace or support cells that are dysfunctional or absent due to degenerative disease or traumatic injury or administered as a means of helping the body mount an effective immune response to cancer. Lineage's clinical programs are in markets with billion dollar opportunities and include four allogeneic ("off-the-shelf") product candidates: (i) OpRegen, a retinal pigment epithelium transplant therapy in Phase 1/2a development for the treatment of dry age-related macular degeneration, which is now being [developed](#) under a worldwide collaboration with Roche and Genentech, a member of the Roche Group; (ii) OPC1, an oligodendrocyte progenitor cell therapy in Phase 1/2a development for the treatment of acute spinal cord injuries; (iii) VAC2, a dendritic cell therapy produced from Lineage's VAC technology platform for immuno-oncology and infectious disease, currently in Phase 1 clinical development for the treatment of non-small cell lung cancer and (iv) ANP1, an auditory neuronal progenitor cell therapy for the potential treatment of auditory neuropathy. For more information, please visit [www.lineagecell.com](http://www.lineagecell.com) or follow the Company on Twitter [@LineageCell](#).

View source version on [businesswire.com](https://www.businesswire.com/news/home/20220324005234/en/): <https://www.businesswire.com/news/home/20220324005234/en/>

### Lineage Cell Therapeutics, Inc. IR

Ioana C. Hone  
([ir@lineagecell.com](mailto:ir@lineagecell.com))  
(442) 287-8963

### Solebury Trout IR

Mike Biega  
([Mbiega@soleburytrout.com](mailto:Mbiega@soleburytrout.com))  
(617) 221-9660

### Russo Partners – Media Relations

Nic Johnson or David Schull  
[Nic.johnson@russopartnersllc.com](mailto:Nic.johnson@russopartnersllc.com)  
[David.schull@russopartnersllc.com](mailto:David.schull@russopartnersllc.com)  
(212) 845-4242

Source: Lineage Cell Therapeutics, Inc.